Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
Details for Australian Patent Application No. 2002325305 (hide)
International Classifications
Event Publications
16 January 2003 Complete Application Filed
Priority application(s): 101 33 915.1 12.07.01 DE
22 May 2003 Application Open to Public Inspection
Published as AU-B-2002325305
15 December 2005 Assignment before Grant
Aventis Pharma Deutschland GmbH The application has been assigned to Sanofi-Aventis Deutschland GmbH
17 May 2007 Application Accepted
Published as AU-B-2002325305
13 September 2007 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2002325306-UV CROSS-LINKABLE MELT ADHESIVES CONTAINING STABILIZERS
2002325304-METHOD FOR MEASURING THE SPATIAL POSITION AND/OR OPENING OF A WORK PIECE
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser